StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen non-GAAP Cost of Sales as % of Product Sales (%) (%)

Form 8-K Reconciliations of GAAP to Non-GAAP Measures

Latest, FY2025
18.3%
Period ended Dec 31, 2025
Change on a year earlier
+0.4 pts
17.9% in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up non-gaap cost of sales as % of product sales (%)

Cite this data

StockData. (2026). Amgen Non-GAAP Cost of Sales as % of Product Sales (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng_cogs_pct

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.